Amgen and MBC BioLabs Announce 2019 Golden Ticket Competition
Amgen is thrilled to award up to two Golden Tickets to high-potential and innovative life science and biotech startups that have the ability to impact patients' lives. 

A Golden Ticket offers:  
  • Priority admission/renewal for one year's use of MBC BioLabs lab bench and Fast-track core facility, providing everything your startup needs to be successful
  • Unique access to Amgen scientific and business leaders
Deadline to apply for an Amgen Golden Ticket is April 29, 2019. To apply, submit your non-confidential company presentation HERE.  Amgen will notify the Golden Ticket winners by June 2019.
Please join us for a Lunch Seminar featuring former Amgen Golden Ticket Winner, SiteOne Therapeutics

Sponsored by

Discovery of Non-opioid Therapeutics for Pain from human Genetics and Natural Products
April 3, 2019
12:00 to 1:30 PM

MBC BioLabs
953 Indiana Street, San Francisco
Lunch served

John Mulcahy PhD, co-founder and Vice President of Research at SiteOne Therapeutics, has a background in synthetic organic chemistry, drug discovery and neuroscience. As a graduate student, he developed technology to prepare synthetic analogues of natural toxins that are potent, small molecule inhibitors of mammalian voltage-gated sodium ion channels. SiteOne has leveraged this technology, as well as structural insights into the binding pose of the natural toxins, to design novel drug candidates with exquisite selectivity for the human nociceptive sodium channel, NaV1.7, as non-opioid therapeutics for the treatment of pain. John received a PhD in Chemistry from Stanford University and AB in Chemistry, Physics and Classics from Harvard.


ScalmiBio is an early stage company developing transformational technology focusing on
oncology applications. We developed a novel technology that converts therapeutic antibodies
into a prodrugs activated specifically within tumor. Therapeutics restricting their activity to
tumor microenvironment will enable broader use of combination treatments, higher therapeutic
doses, and limit side effects.